CNE1000012B3
CNE1000012B3
SH PHARMA
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 40.9B EUR | 42.28B EUR | 42.83B EUR | 42.09B EUR |
Enterprise Value | 68.26B EUR | 58.69B EUR | 65.21B EUR | 61.65B EUR |
Valuation Multiples | ||||
Trailing P/E | 7.66x | 10.36x | 8.36x | 8.36x |
Forward P/E | 5.81x | -- | -- | -- |
Price to Sales | 0.14x | 0.2x | 0.2x | 0.2x |
Price to Book | 0.45x | 0.54x | 0.55x | 0.55x |
EV/Revenue | 0.24x | 0.27x | 0.3x | 0.29x |
EV/EBITDA | 6.23x | 5.33x | 5.07x | 6.2x |
Price to FCF (P/FCF) | 32.15x | 6.5x | 10.22x | 14.24x |
EV/FCF | 53.65x | 9.03x | 15.55x | 20.86x |
FCF Yield | 3.11% | 15.37% | 9.79% | 7.02% |